Aspira Women’s Health Appoints Mr. John Ragard to its Board of Directors
Aspira Women's Health Inc. (Nasdaq: AWH) has appointed Mr. John Ragard to its Board of Directors. Mr. Ragard brings over 46 years of experience in public equity investment and Wall Street. He has successfully managed several billion-dollar portfolios throughout his career. The company's Chairwoman, Ms. Jannie Herchuk, and CEO, Nicole Sandford, both expressed enthusiasm about Mr. Ragard's addition to the board, citing his wealth of experience and understanding of Wall Street as valuable assets for Aspira's growth strategy.
Mr. Ragard's extensive background includes roles as a venture capital investor, public equity buy-side analyst, and portfolio manager. He is currently a Senior Investment Advisor at Wayve Capital Management and has previously held positions at Spouting Rock and Friess Associates, where he consistently outperformed market benchmarks. Mr. Ragard expressed excitement about joining Aspira's board and contributing to the company's future success.
Aspira Women's Health Inc. (Nasdaq: AWH) ha nominato il Sig. John Ragard come membro del proprio Consiglio di Amministrazione. Il Sig. Ragard porta con sé oltre 46 anni di esperienza negli investimenti in equity pubblici e a Wall Street. Ha gestito con successo diversi portafogli da miliardi di dollari nel corso della sua carriera. La Presidente dell'azienda, la Sig.ra Jannie Herchuk, e l'Amministratore Delegato, Nicole Sandford, hanno entrambe espresso entusiasmo riguardo all'aggiunta del Sig. Ragard al consiglio, citando la sua ricchezza di esperienza e comprensione di Wall Street come beni preziosi per la strategia di crescita di Aspira.
Il vasto background del Sig. Ragard include ruoli come investitore di venture capital, analista buy-side di equity pubblica e gestore di portafoglio. Attualmente è un Senior Investment Advisor presso Wayve Capital Management e ha precedentemente ricoperto posizioni presso Spouting Rock e Friess Associates, dove ha costantemente superato i benchmark di mercato. Il Sig. Ragard ha espresso entusiasmo per l'ingresso nel consiglio di Aspira e per il contributo al futuro successo dell'azienda.
Aspira Women's Health Inc. (Nasdaq: AWH) ha nombrado al Sr. John Ragard en su Junta Directiva. El Sr. Ragard aporta más de 46 años de experiencia en inversiones en capital público y en Wall Street. Ha gestionado con éxito varios portafolios de miles de millones de dólares a lo largo de su carrera. La Presidenta de la compañía, la Sra. Jannie Herchuk, y la CEO, Nicole Sandford, expresaron entusiasmo por la incorporación del Sr. Ragard a la junta, citando su rica experiencia y comprensión de Wall Street como activos valiosos para la estrategia de crecimiento de Aspira.
El extenso historial del Sr. Ragard incluye roles como inversionista de capital de riesgo, analista buy-side de capital público y gestor de portafolio. Actualmente es Asesor de Inversiones Senior en Wayve Capital Management y ha ocupado posiciones previamente en Spouting Rock y Friess Associates, donde consistentemente superó los índices de referencia del mercado. El Sr. Ragard expresó su entusiasmo por unirse a la junta de Aspira y contribuir al éxito futuro de la empresa.
Aspira Women's Health Inc. (Nasdaq: AWH)가 존 래가드를 이사회에 임명했습니다. 래가드는 46년 이상의 공공 주식 투자 및 월스트리트 경험을 가지고 있습니다. 그는 경력 전반에 걸쳐 수십억 달러의 포트폴리오를 성공적으로 관리해 왔습니다. 회사의 의장인 제이니 허치크와 CEO인 니콜 샌포드 모두 래가드의 이사회 합류에 대해 열정을 표명하며, 그의 풍부한 경험과 월스트리트에 대한 이해가 아스피라의 성장 전략에 귀중한 자산이라고 언급했습니다.
래가드의 광범위한 배경에는 벤처 자본 투자자, 공공 주식 매수 측 분석가 및 포트폴리오 관리자로서의 역할이 포함됩니다. 그는 현재 Wayve Capital Management의 수석 투자 자문가이며, Spouting Rock 및 Friess Associates에서 이전에 직책을 맡았던 경험이 있습니다. 래가드는 아스피라의 이사회에 합류하게 되어 기쁘며, 회사의 미래 성공에 기여하기를 원한다고 밝혔습니다.
Aspira Women's Health Inc. (Nasdaq: AWH) a nommé M. John Ragard à son Conseil d'Administration. M. Ragard apporte plus de 46 ans d'expérience dans l'investissement en capital public et à Wall Street. Il a géré avec succès plusieurs portefeuilles de plusieurs milliards de dollars tout au long de sa carrière. La Présidente de l'entreprise, Mme Jannie Herchuk, et la PDG, Nicole Sandford, ont toutes deux exprimé leur enthousiasme quant à l'ajout de M. Ragard au conseil, citant sa richesse d'expérience et sa compréhension de Wall Street comme des atouts précieux pour la stratégie de croissance d'Aspira.
Le vaste parcours de M. Ragard comprend des rôles en tant que investisseur en capital-risque, analyste d'actions publiques côté achat et gestionnaire de portefeuille. Il est actuellement Conseiller Senior en Investissements chez Wayve Capital Management et a précédemment occupé des postes chez Spouting Rock et Friess Associates, où il a constamment surpassé les indices du marché. M. Ragard a exprimé son enthousiasme à rejoindre le conseil d'Aspira et à contribuer au succès futur de l'entreprise.
Aspira Women's Health Inc. (Nasdaq: AWH) hat Herrn John Ragard in seinen Vorstand berufen. Herr Ragard bringt über 46 Jahre Erfahrung im Bereich öffentliche Aktieninvestitionen und an der Wall Street mit. Er hat im Laufe seiner Karriere erfolgreich mehrere milliardenschwere Portfolios verwaltet. Die Vorsitzende des Unternehmens, Frau Jannie Herchuk, und CEO Nicole Sandford äußerten beide ihre Begeisterung über Herrn Ragards Hinzufügung zum Vorstand und bezeichneten sein reiches Erfahrung und Verständnis für die Wall Street als wertvolle Ressourcen für die Wachstumsstrategie von Aspira.
Herr Ragards umfassender Hintergrund umfasst Rollen als Wagniskapitalinvestor, öffentliche Aktien-Analyst und Portfoliomanager. Derzeit ist er Senior Investment Advisor bei Wayve Capital Management und hat zuvor Positionen bei Spouting Rock und Friess Associates innegehabt, wo er stets die Marktbenchmarks übertraf. Herr Ragard äußerte seine Vorfreude auf seinen Eintritt in den Vorstand von Aspira und darauf, zum künftigen Erfolg des Unternehmens beizutragen.
- Appointment of John Ragard, an experienced Wall Street professional, to the Board of Directors
- Ragard brings 46 years of experience in public equity investment and portfolio management
- Potential for improved investor relations and attraction of long-term investors
- Ragard's history of outperforming market benchmarks in previous roles
- None.
Mr. Ragard further strengthens the Board bringing more than 46 years of significant public equity investment and Wall Street experience
AUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mr. John Ragard to its Board of Directors. Mr. Ragard is an accomplished executive with extensive experience successfully managing several billion-dollar portfolios over his career.
“We are pleased to welcome John to our Board of Directors,” said Ms. Jannie Herchuk, Chairwoman of the Board at Aspira Women’s Health. “John brings a wealth of experience and a keen understanding of Wall Street, having been a successful money manager for the past four decades. He will be an important voice on our Board as we continue to build Aspira to be a world-class company delivering a new standard of care in women’s health.”
Nicole Sandford, Chief Executive Officer of Aspira Women’s Health said, “John is an excellent addition to the Board. As a seasoned investment professional, John understands what Aspira needs to do to attract and retain long-term investors. He has followed the company closely for many years and, as a result, will quickly add valuable insight to help us execute the next phase of accelerated growth.”
Mr. John Ragard spent over 46 years as a venture capital investor, public equity buy-side analyst, and portfolio manager. Mr. Ragard is currently a Senior Investment Advisor at Wayve Capital Management after having been a portfolio manager at Spouting Rock for over six years, where he co-managed a small-cap growth portfolio that outperformed the benchmark over the 5-year and since-inception periods. Prior to Spouting Rock, Mr. Ragard was a portfolio manager at Friess Associates where he outperformed the Russell 3000 Growth Index by over 400 basis points annually for over 20 years. Mr. Ragard received his Bachelor of Science in Economics cum laude from the Wharton School and is a Chartered Financial Analyst.
Mr. Ragard added, “I am excited to join this group of committed directors. I have long believed in the promise of Aspira’s compelling portfolio, and I look forward to working closely with them as we take the company to the next level.”
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of
Our in-development test pipeline is designed to expand our ovarian cancer portfolio and addresses the tremendous need for noninvasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, our OvaMDxSM risk assessment is designed to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, EndoCheckSM is the first-ever noninvasive test designed to identify endometriomas, one of the most commonly occurring forms of endometriosis. The EndoMDxSM test is designed to combine microRNA and protein biomarkers with patient data to identify all endometriosis.
Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the pipeline development and other statements that are predictive in nature. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as “designed to,” “expect,” “plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release and other factors that may cause such differences include the satisfaction of customary closing conditions related to the offering and the expected timing of the closing of the offering. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 10-K, for the fiscal year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira’s expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company’s assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor Relations Contact:
Nicole Sandford
Chief Executive Officer
Investors@aspirawh.com
FAQ
Who is the new Board member appointed by Aspira Women's Health (AWH)?
What is John Ragard's background and experience relevant to Aspira Women's Health (AWH)?
How might John Ragard's appointment benefit Aspira Women's Health (AWH)?
What is Aspira Women's Health's (AWH) focus as a company?
